Labiotech.eu

News and Trends 13 Dec 2022

Watch: Interview with Medicon Village CEO Petter Hartman

Medicon Village, in Lund, southern Sweden, is part of a cluster of life science research and development, together with actors such as the European Spallation Source (ESS), the BioMedical Centre (BMC) at Lund University and the Max IV Laboratory. Medicon Village is divided into two companies – Medicon Village Fastighets AB and Medicon Village Innovation […]

December 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Dec 2022

Ascletis announces positive COVID-19 trial results

Ascletis Pharma Inc. has announced positive topline results from its phase I multiple ascending dose (MAD) study in healthy subjects for oral RNA-dependent RNA polymerase (RdRp) inhibitor ASC10 for COVID-19 treatment. Ascletis’ ASC10 is an innovative orally available double prodrug, which has a new and differentiated chemical structure from the single prodrug molnupiravir. After oral […]

December 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 13 Dec 2022

Therabest and Glycotope to assess breast cancer combination treatment

Therabest USA. Inc, Therabest Korea and Glycotope GmbH have signed an agreement to assess the clinical development of Therabest’s EiNK (enhanced iPSC-derived NK) cell therapy, TB-100, in combination with Glycotope’s immuno-cytokine, GT-00AxIL15 in triple-negative breast cancer (TNBC) patients. NK (natural killer) cell therapies from various cell sources have demonstrated exciting results in early clinical trials […]

December 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Dec 2022

Blood clotting research holds hope for sepsis

Researchers from the University of Birmingham in the U.K., who identified a novel mechanism for platelet activation in pathogenic blood clotting (thrombosis), are now turning their attention to sepsis. Identified by associate professor Julie Rayes and Martina Colicchia from the Birmingham Platelet Group, and described in a recent paper in Blood, this previously unknown axis […]

December 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Dec 2022

Poolbeg influenza trial successfully completed

Poolbeg Pharma has received initial results having completed its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza. The study showed no further clinical activity is required to complete the objectives of the trial, bringing the recruitment […]

December 13, 2022 - 3 minutesmins - By Jim Cornall

Opinion 12 Dec 2022

Artificial intelligence: a new era in rare genetic disease diagnosis

Despite the onset of the genomics era, rare disease diagnosis remains a challenge. Nostos Genomics’ co-founder, Rocío Acuña Hidalgo, and chief operating officer, Ansgar Lange, shed light on how artificial intelligence (AI) could fill in the gaps. It is estimated that 300 million people worldwide are affected by rare diseases and around 80% of these […]

December 12, 2022 - 6 minutesmins - By External Contributor

News and Trends 12 Dec 2022

Japanese research offers hope for Fukuyama muscular dystrophy patients

Fukuyama congenital muscular dystrophy (FCMD) is the second most common form of childhood muscular dystrophy in Japan. The disease manifests itself in the form of a severe neuromuscular disorder. One form of FCMD is caused by a genetic abnormality in the fukutin (FKTN) gene. The genetic anomaly blocks the chemical glycosylation of a biologically important […]

December 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 Dec 2022

OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data

OSE Immunotherapeutics SA has presented the latest preclinical data on the use of its anti-IL-7 receptor (IL-7R) antagonist OSE-127 for the treatment of B- and T-Cell acute lymphoblastic leukemia (B- and T-ALL). The information was provided at the American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The preclinical data on OSE-127 presented […]

December 12, 2022 - 4 minutesmins - By Jim Cornall

brain cancer glioblastoma divide and conquer

News and Trends 12 Dec 2022

Enterome completes patient enrollment for recurrent glioblastoma study

Enterome has completed patient enrollment in its phase 2 clinical trial (ROSALIE) evaluating its lead OncoMimics candidate, EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab) in patients with first progression/recurrence of glioblastoma, an aggressive form of brain cancer. Enterome is a French clinical stage company developing first-in-class immunomodulatory drugs […]

December 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Dec 2022

Studying the global spread of antimicrobial resistance

An international research team has provided new information about what drives the global spread of genes responsible for antimicrobial resistance (AMR) in bacteria. The collaborative study, led by researchers at the Quadram Institute and the University of East Anglia in the U.K., brought together experts from France, Canada, Germany and the U.K. and will provide […]

December 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 Dec 2022

Antibody discovery could lead to new therapies to tackle Strep A

Researchers at Lund University in Sweden have discovered an antibody with the potential to protect against Strep A infection, as well as a rare form of antibody binding, that leads to an effective immune response against bacteria. The researchers say the discovery could explain why so many group A strep vaccines have failed. The results […]

December 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 Dec 2022

Step Pharma announces promising pre-clinical cancer data

Step Pharma has announced encouraging pre-clinical data on its first-in-class, highly selective, orally bioavailable CTPS1 inhibitor, STP938. The data were presented at the 64th American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The data presented by Step Pharma collaborators demonstrates the potential of STP938, a highly selective CTPS1 inhibitor, as a therapeutic […]

December 12, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Watch: Interview with Medicon Village CEO Petter Hartman

Ascletis announces positive COVID-19 trial results

Therabest and Glycotope to assess breast cancer combination treatment

Blood clotting research holds hope for sepsis

Poolbeg influenza trial successfully completed

Artificial intelligence: a new era in rare genetic disease diagnosis

Japanese research offers hope for Fukuyama muscular dystrophy patients

OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data

Enterome completes patient enrollment for recurrent glioblastoma study

Studying the global spread of antimicrobial resistance

Antibody discovery could lead to new therapies to tackle Strep A

Step Pharma announces promising pre-clinical cancer data

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!